WO2012104788A3 - Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation - Google Patents

Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation Download PDF

Info

Publication number
WO2012104788A3
WO2012104788A3 PCT/IB2012/050452 IB2012050452W WO2012104788A3 WO 2012104788 A3 WO2012104788 A3 WO 2012104788A3 IB 2012050452 W IB2012050452 W IB 2012050452W WO 2012104788 A3 WO2012104788 A3 WO 2012104788A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions containing
containing same
angiogenic compounds
substituted
Prior art date
Application number
PCT/IB2012/050452
Other languages
English (en)
Other versions
WO2012104788A2 (fr
Inventor
Jean-Jacques Feige
Agnès CASTAN
Delphine QUELARD
Martine Demeunynck
Jean-François CONSTANT
Caroline Barette
Original Assignee
Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique filed Critical Centre National De La Recherche Scientifique
Publication of WO2012104788A2 publication Critical patent/WO2012104788A2/fr
Publication of WO2012104788A3 publication Critical patent/WO2012104788A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (A) ayant une activité anti-angiogénique et/ou antitumorale, les compositions pharmaceutiques les comprenant et leur utilisation dans le traitement du cancer. (substitué) N-(CH2)m-A-Rc Oú A est une liaison, Het-(CH2)1-6 ou NH-(CH2)1-6 et Rc est O-substitué ou N-substitué
PCT/IB2012/050452 2011-01-31 2012-01-31 Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation WO2012104788A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1100277A FR2970965A1 (fr) 2011-01-31 2011-01-31 Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation
FR1100277 2011-01-31

Publications (2)

Publication Number Publication Date
WO2012104788A2 WO2012104788A2 (fr) 2012-08-09
WO2012104788A3 true WO2012104788A3 (fr) 2013-04-11

Family

ID=43881047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050452 WO2012104788A2 (fr) 2011-01-31 2012-01-31 Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation

Country Status (2)

Country Link
FR (1) FR2970965A1 (fr)
WO (1) WO2012104788A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105669549B (zh) * 2016-02-25 2019-04-19 青岛科技大学 一种萘二甲酰胺基乙基萘乙酸酯类化合物及其应用
CN105669550B (zh) * 2016-02-25 2018-11-16 青岛科技大学 一种萘二甲酰胺基乙基己酸酯类化合物及其应用
CN105646348B (zh) * 2016-02-25 2018-04-20 青岛科技大学 一种萘二甲酰胺基萘乙酰基硫脲类化合物及其用途
JP2023544790A (ja) * 2020-10-10 2023-10-25 湘北威爾曼制薬股▲ふん▼有限公司 縮合環ジイミド誘導体、その製造方法と使用
WO2023179205A1 (fr) * 2022-03-23 2023-09-28 湘北威尔曼制药股份有限公司 Dérivé de diimide, son procédé de préparation et son utilisation

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305008A2 (fr) * 1987-08-25 1989-03-01 Oxi-Gene, Inc. Thérapie tuant cellules tumorales ou cancéreuses et agents utiles à cet effet
JPH10316649A (ja) * 1997-05-20 1998-12-02 Hiroyoshi Hidaka ナフタレンスルホンアミド誘導体及びこれを含有する医薬
WO1999026945A1 (fr) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE αvβ¿3?
WO1999065516A1 (fr) * 1998-06-17 1999-12-23 Yeda Research And Development Co. Ltd. Methodes et compositions pour traiter les maladies ayant pour origine l'action de la tranglutaminase
EP1085011A1 (fr) * 1999-09-15 2001-03-21 Oridigm Corporation Polyamine analogues comme agents therapeutiques et diagnostiques
JP2001172257A (ja) * 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
WO2001085730A1 (fr) * 2000-05-09 2001-11-15 Astrazeneca Ab Derives de pyrido' 1,2-alpha pyrazine et de piperidine servant de ligands au recepteur de neuropeptide y y5
EP1787679A1 (fr) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Utilisation des composés attachés au sigma recepteur pour le traitement de la douleur associée avec diabète
WO2007076055A2 (fr) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions et methodes comprenant l'utilisation d'antagonistes du recepteur active par des proteases
WO2008063760A2 (fr) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Méthodes de traitement de cancer ciblant la transglutaminase
WO2009089537A2 (fr) * 2008-01-11 2009-07-16 Northwestern University Composés anticancéreux
WO2009114729A2 (fr) * 2008-03-14 2009-09-17 Irm Llc Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
WO2009144344A2 (fr) * 2008-05-20 2009-12-03 Universidad De Granada Composé à base de vinylsulfone pour le marquage de biomolécules, sa préparation et ses utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789125A (fr) * 1971-09-24 1973-03-22 Toms River Chemical Corp Colorants substantifs disazoiques pour papier
DE2601376A1 (de) * 1976-01-15 1977-07-21 Bayer Ag Phenoxycarbonsaeure-aryloxy(thio)carbonylaminomethylester, verfahren zu ihrer herstellung sowie ihre verwendung zur regulierung des pflanzenwachstums
WO2008075955A2 (fr) * 2006-12-21 2008-06-26 Stichting Voor De Technische Wetenschappen Procédé de préparation de triazoles trisubstitués en 1,4,5 et de triazoles trisubstitués en 3,4,5

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305008A2 (fr) * 1987-08-25 1989-03-01 Oxi-Gene, Inc. Thérapie tuant cellules tumorales ou cancéreuses et agents utiles à cet effet
JPH10316649A (ja) * 1997-05-20 1998-12-02 Hiroyoshi Hidaka ナフタレンスルホンアミド誘導体及びこれを含有する医薬
WO1999026945A1 (fr) * 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE αvβ¿3?
WO1999065516A1 (fr) * 1998-06-17 1999-12-23 Yeda Research And Development Co. Ltd. Methodes et compositions pour traiter les maladies ayant pour origine l'action de la tranglutaminase
EP1085011A1 (fr) * 1999-09-15 2001-03-21 Oridigm Corporation Polyamine analogues comme agents therapeutiques et diagnostiques
JP2001172257A (ja) * 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
WO2001085730A1 (fr) * 2000-05-09 2001-11-15 Astrazeneca Ab Derives de pyrido' 1,2-alpha pyrazine et de piperidine servant de ligands au recepteur de neuropeptide y y5
EP1787679A1 (fr) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Utilisation des composés attachés au sigma recepteur pour le traitement de la douleur associée avec diabète
WO2007076055A2 (fr) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions et methodes comprenant l'utilisation d'antagonistes du recepteur active par des proteases
WO2008063760A2 (fr) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Méthodes de traitement de cancer ciblant la transglutaminase
WO2009089537A2 (fr) * 2008-01-11 2009-07-16 Northwestern University Composés anticancéreux
WO2009114729A2 (fr) * 2008-03-14 2009-09-17 Irm Llc Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
WO2009144344A2 (fr) * 2008-05-20 2009-12-03 Universidad De Granada Composé à base de vinylsulfone pour le marquage de biomolécules, sa préparation et ses utilisations

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
CAUJOLLE R ET AL: "Aminothiazine and aminothiazole open analogs of levamisole: synthesis and anthelminthic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 24, no. 3, 1 May 1989 (1989-05-01), pages 287 - 291, XP023870154, ISSN: 0223-5234, [retrieved on 19890501], DOI: DOI:10.1016/0223-5234(89)90011-1 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HELLMANN, HEINRICH ET AL: "N - Dialkylaminomethylsulfonamides", XP002634743, retrieved from STN Database accession no. 1959:34823 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HIDAKA, HIROYOSHI ET AL: "Naphthalenesulfonamides and their uses for calmodulin inhibitors and pharmaceuticals", XP002634746, retrieved from STN Database accession no. 1998:768073 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UCHIDA, YASUYOSHI ET AL: "Preparation of nitro compounds for treatment of angina pectoris and for prevention of restenosis after percutaneous transluminal coronary angioplasty", XP002683479, retrieved from STN Database accession no. 1997:526102 *
DATABASE INTEGRITY [Online] Prous Science; 2008, "UNBS5162: A new naphthalimide derivative with radiosensitizing and anti-angiogenic activity entering phase I", XP002683484, Database accession no. 449989 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 November 2007 (2007-11-13), XP002683481, retrieved from stn accession no. 953258-96-3 Database accession no. 953258-96-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 November 2007 (2007-11-15), XP002683480, retrieved from STN accession no. 953930-49-9 Database accession no. 953930-49-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 November 2007 (2007-11-15), XP002683482, retrieved from stn accession no. 953931-16-3 Database accession no. 953931-16-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 29 September 2011 (2011-09-29), XP002683483, retrieved from stn accession no. 1333982-06-1 Database accession no. 1333982-06-1 *
DOTSON M J ET AL: "Selective inhibition of schistosome acetylcholinesterase by dansylated acetylcholine analogs", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. C. COMPARATIVEPHARMACOLOGY, PERGAMON PRESS , OXFORD, GB, vol. 68, no. 2, 1 January 1981 (1981-01-01), pages 229 - 230, XP025559281, ISSN: 0306-4492, [retrieved on 19810101], DOI: 10.1016/0306-4492(81)90020-4 *
FROHLICH R F G ET AL: "1-Deoxynojirimycins with dansyl capped N-substituents as probes for Morbus Gaucher affected cell lines", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 345, no. 10, 2 July 2010 (2010-07-02), pages 1371 - 1376, XP027118792, ISSN: 0008-6215, [retrieved on 20100424] *
MAC NEIL S ET AL: "ANTIPROLIFERATIVE EFFECTS ON KERATINOCYTES OF A RANGE OF CLINICALLY USED DRUGS WITH CALMODULIN ANTAGONIST ACTIVITY", BRITISH JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 128, no. 2, 1 February 1993 (1993-02-01), pages 143 - 150, XP000872044, ISSN: 0007-0963 *
MARTIN RECK: "Examining the safety profile of angiogenesis inhibitors: implications for clinical practice", TARGETED ONCOLOGY, vol. 5, no. 4, 1 December 2010 (2010-12-01), pages 257 - 267, XP055038235, ISSN: 1776-2596, DOI: 10.1007/s11523-010-0159-0 *
SPINELLI A M ET AL: "EFFECTS OF PROCESSING ON THE AMINE CONTENT OF PORK BELLIES", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 22, no. 6, 1 January 1974 (1974-01-01), pages 1026 - 1028, XP009020346, ISSN: 0021-8561, DOI: 10.1021/JF60196A026 *
THOMAS W. BELL ET AL: "Synthesis and Structure-Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (CADA) Analogues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 4, 1 February 2006 (2006-02-01), pages 1291 - 1312, XP055038078, ISSN: 0022-2623, DOI: 10.1021/jm0582524 *
WANG X M ET AL: "SPECTROSCOPIC STUDY OF THE INTERACTION BETWEEN NEW FLUORESCENT DYES WITH NUCLEIC ACIDS", CHINESE CHEMICAL LETTERS, ELSEVIER LTD, GB, vol. 10, no. 12, 1 January 1999 (1999-01-01), pages 1045 - 1048, XP008017889, ISSN: 1001-8417 *
ZIESSEL R ET AL: "CONVENIENT AND MULTISTEP PREPARATION OF OLIGOPYRIDINES BEARING MULTIPLE DANSYL AND NITROXIDE RADICALS", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, no. 14, 1 January 2003 (2003-01-01), pages 2145 - 2154, XP001205895, ISSN: 0039-7881, DOI: 10.1055/S-2003-42083 *

Also Published As

Publication number Publication date
WO2012104788A2 (fr) 2012-08-09
FR2970965A1 (fr) 2012-08-03

Similar Documents

Publication Publication Date Title
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
EP4071149A3 (fr) Composés hétérocycliques et leurs utilisations
WO2014008458A3 (fr) Benzamides n-substitués et leurs procédés d'utilisation
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2012061418A3 (fr) Benzamides et nicotinamides en tant que modulateurs de syk
EP4219465A3 (fr) Inhibiteurs de prmt5 et leurs utilisations
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
GEP20146197B (en) New compounds
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
WO2014097151A3 (fr) Inhibiteurs d'autotaxine
MX2015008100A (es) Composiciones que comprenden un compuesto de triazol.
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
MX2009000884A (es) Derivados de piridizinona.
MY172924A (en) Neprilysin inhibitors
WO2014031438A3 (fr) Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
UA109199C2 (uk) Дигідропіридинові сполуки, корисні для лікування від залежності, викликаної агентами, що стимулюють вироблення дофаміну
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
IN2014CN03803A (fr)
WO2012101011A3 (fr) Nouveaux dérivés d'arylbenzocycloalkylamides
MX2013008696A (es) Composicion saborizante que comprende mentol y mentano-carboxamidas.
JO2741B1 (en) Spiro-cyclic nitroblast as protease inhibitors
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12728775

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12728775

Country of ref document: EP

Kind code of ref document: A2